Abstract
Therapeutic antibodies are recombinant proteins used in the treatment of cancer. There is a new generation of monoclonal antibodies with activity against cancer cells, known as antibody-drug conjugates. These molecules are made up of three elements: a monoclonal antibody, a highly potent cytotoxic drug, and a chemical linker that binds them together. The antibody recognizes tumor antigens, thereby allowing targeted delivery of the cytotoxic agent to cancer cells. After recognizing its antigen, the antibody-drug conjugate is endocytosed by the target cells, where the protein fraction is degraded into lysosomes, releasing the cytotoxic drug. This article reviews antibody-drug conjugates general characteristics and describes the clinical evidence of efficacy and safety of the first four approved by regulatory agencies in the United States and Europe.
Translated title of the contribution | Antibody-drug conjugates: The new generation of biotechnological therapies against cancer |
---|---|
Original language | English |
Pages (from-to) | 228-235 |
Number of pages | 8 |
Journal | Gaceta Medica de Mexico |
Volume | 156 |
Issue number | 3 |
DOIs | |
State | Published - 1 May 2020 |
Keywords
- Antibody-drug conjugates
- Brentuximab vedotin
- Gemtuzumab ozogamicin
- Inotuzumab ozogamicin
- Trastuzumab emtansine